StockDuty ← Dashboard Aug 31, 2026 01:39 PM ET
SignalFDA/Bio

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Phase 3 trial initiation marks a pivotal clinical catalyst for AXS-05.

What changed
Why it matters
Phase 3 trial initiation marks a pivotal clinical catalyst for AXS-05.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →